Statistics for Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Total visits
| views | |
|---|---|
| Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) | 218 |
Total visits per month
| views | |
|---|---|
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
File Visits
| views | |
|---|---|
| JCO661595.pdf | 215 |
Top country views
| views | |
|---|---|
| United States | 177 |
| Germany | 9 |
| Ukraine | 6 |
| Canada | 4 |
| Russia | 4 |
| China | 2 |
| United Kingdom | 2 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 52 |
| Fairfield | 31 |
| Houston | 21 |
| Ann Arbor | 9 |
| Jacksonville | 7 |
| Cambridge | 6 |
| Kiez | 6 |
| Kiev | 5 |
| Toronto | 4 |
| Lake Mary | 3 |
| Saint Petersburg | 3 |
| Baltimore | 2 |
| Beijing | 2 |
| Gunzenhausen | 2 |
| San Francisco | 2 |
| Costa Mesa | 1 |
| Indianapolis | 1 |
| Kharkov | 1 |
| Liversedge | 1 |
| Moscow | 1 |
| New York | 1 |
| Philadelphia | 1 |
| Plauen | 1 |
| Scottsdale | 1 |
| Seremban | 1 |